Table: Comparison of trials of chemotherapy ± FLT3 multikinase inhibitor in previously untreated mutant FLT3 AML
| Trial . | Ref. . | Median age (range), y . | N (FLT3 ITD %) . | Agent . | Agent % vs control % (y) . | Transplant rate overall CR1 % . | Notes . | ||
|---|---|---|---|---|---|---|---|---|---|
| OS . | DFS . | ||||||||
| C10603/Ratify | 9 | 49 (18-59) | 714 (77) | Midostaurin | 51 vs 43 (5) | 46 vs 36 (5) | 57 | 25 | Benefit seen in all FLT3 mutant subgroups |
| AML 15/17 | 1 | 49 (5-68) | 500 (74) | Lestaurtinib | 46 vs 45 (5) | 40 vs 36 (5) | 45 | 25 | OS benefit in patients with significant FLT3 inhibition by PIA or on GO + azole |
| Trial . | Ref. . | Median age (range), y . | N (FLT3 ITD %) . | Agent . | Agent % vs control % (y) . | Transplant rate overall CR1 % . | Notes . | ||
|---|---|---|---|---|---|---|---|---|---|
| OS . | DFS . | ||||||||
| C10603/Ratify | 9 | 49 (18-59) | 714 (77) | Midostaurin | 51 vs 43 (5) | 46 vs 36 (5) | 57 | 25 | Benefit seen in all FLT3 mutant subgroups |
| AML 15/17 | 1 | 49 (5-68) | 500 (74) | Lestaurtinib | 46 vs 45 (5) | 40 vs 36 (5) | 45 | 25 | OS benefit in patients with significant FLT3 inhibition by PIA or on GO + azole |
CR1, first complete remission; DFS, disease-free survival; GO, gemtuzumab ozogamicin; PIA, plasma inhibitory assay; Ref., reference.